Last reviewed · How we verify
IMM01
IMM01 is an immunotherapeutic agent designed to enhance anti-tumor immune responses, likely through modulation of immune checkpoint pathways or T-cell activation.
At a glance
| Generic name | IMM01 |
|---|---|
| Also known as | IMM01 Ingection, SIRPα Fc, Timdarpacept, IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG1 fusion protein |
| Sponsor | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While specific mechanistic details for IMM01 are limited in public literature, the drug appears to be developed as an immuno-oncology therapeutic by ImmuneOnco Biopharmaceuticals. Given the company's focus and the phase 3 status, it likely targets immune checkpoints or enhances T-cell mediated tumor killing, though the exact molecular target requires confirmation from clinical trial data.
Approved indications
Common side effects
Key clinical trials
- INTERMEDIATE-SIZE PATIENT POPULATIONS EXPANDED ACCESS TO TREATMENT FOR SARCOPENIC OBESITY
- Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness (PHASE2)
- IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2) (PHASE3)
- Safety and Tolerability of IMM01-STEM in Patients With Muscle Atrophy Related to Knee Osteoarthritis. (PHASE1, PHASE2)
- A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma (PHASE3)
- A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome (PHASE1, PHASE2)
- Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |